Hemophagocytic Lymphohistiocytosis Unknown Status Phase 3 Trials for Pegaspargase (DB00059)

Back to Hemophagocytic Lymphohistiocytosis

Also known as: Hemophagocytic Lymphohistiocytosis (HLH) / Haemophagocytic Lymphohistiocytosis / Hemophagocytic Lymphohistiocytoses / Hemophagocytic Lymphohisticytosis / Hemophagocytic lymphohistiocytosis (disorder) / Lymphohistiocytosis, Hemophagocytic / Primary hemophagocytic lymphohistiocytosis / Primary haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis (disorder) / Familial Hemophagocytic Lymphocytosis / Familial haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis

Indication	Status	Phase
DBCOND0029166 (Hemophagocytic Lymphohistiocytosis)	Unknown Status	3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT02912702	L-DEP as an Initial Treatment for EBV-HLH	Treatment	Dexamethasone (DB01234) Doxorubicin (DB00997) Etoposide (DB00773) Methylprednisolone (DB00959) Pegaspargase (DB00059)
NCT02631109	L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis	Treatment	Doxorubicin (DB00997) Etoposide (DB00773) Methylprednisolone (DB00959) Pegaspargase (DB00059)